SCHEMBL187419

SCHEMBL187419

CN(C)[C@H]1CCCC[C@@H]1N

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20370299 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL2549893 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL5676529 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL145250 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL30962277 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL1440790 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL1071722 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL13993046 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL113492 1.00 THRB (0.47) THRBMEN1KMT2A
SCHEMBL15572000 0.97 THRB (0.45) THRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12122788-B2 Process of making CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-10-22 US claimed
CN-115894884-B Trifunctional organic catalyst and preparation method and application thereof 浙江大学 2024-07-05 CN claimed
US-20240166595-A1 PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS GENENTECH, INC. (US) 2024-05-23 US claimed
EP-4347574-A1 PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS Genentech, Inc. (US) 2024-04-10 EP claimed
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-12-14 US claimed
US-20230234956-A1 METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS RECURIUM IP HOLDINGS, LLC 2023-07-27 US claimed
EP-3851441-B1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE HOFFMANN LA ROCHE (CH) 2023-06-28 EP claimed
CN-115894884-A Trifunctional organic catalyst, and preparation method and application thereof 浙江大学 2023-04-04 CN claimed
WO-2022251567-A1 PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS GENENTECH, INC. (US) 2022-12-01 WO claimed
EP-3851441-A1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE F. Hoffmann-La Roche AG (CH) 2021-07-21 EP claimed
EP-3555107-B1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE HOFFMANN LA ROCHE (CH) 2021-02-17 EP claimed
US-10781219-B2 Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino) propanamide GENENTECH, INC. (US) 2020-09-22 US claimed
EP-3555107-A1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE H. Hoffnabb-La Roche Ag (CH) 2019-10-23 EP claimed
US-20190292201-A1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROP AN AMIDE GENENTECH, INC. (US) 2019-09-26 US claimed
CN-109046449-A A kind of tertiary amine-Thiourea bifunctional chiral catalyst and the preparation method and application thereof 石家庄学院 2018-12-21 CN claimed
WO-2018109204-A1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE F. HOFFMANN-LA ROCHE AG (CH) 2018-06-21 WO claimed
EP-1442050-B1 LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF MALESCI SAS (IT) 2006-09-13 EP claimed
WO-2026103930-A1 IMIDAZOL-2-ONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF 西藏海思科制药有限公司 2026-05-21 WO disclosed
US-4145435-A 2-AMINOCYCLOALIPHATIC AMIDE COMPOUNDS THE UPJOHN COMPANY (US) 1979-03-20 US disclosed
US-4098904-A ANALGESIC N-(2-AMINOCYCLOALIPHATIC)BENZAMIDES THE UPJOHN COMPANY (US) 1978-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399343-A1 PROCESS OF MAKING CFTR MODULATORS CFTR, SLC26A4, TMEM109 THRB 2612/4885MEN1 2440/4885KMT2A 4522/4885
US-10781219-B2 Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino) propanamide CACNA1D, CACNA1B, KCNMB4 THRB 3576/4885MEN1 4033/4885KMT2A 1843/4885
US-20190292201-A1 PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROP AN AMIDE CACNG4, KCNJ4, CYP2J2 THRB 3413/4885MEN1 4156/4885KMT2A 1866/4885
US-20230234956-A1 METHODS OF MAKING WEE1 INHIBITOR COMPOUNDS WEE1, WEE2, CCNE1 THRB 4259/4885MEN1 535/4885KMT2A 1139/4885
US-20240166595-A1 PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS CYP2C18, CYP2C19, CYP4X1 THRB 3901/4885MEN1 3393/4885KMT2A 2322/4885
US-12122788-B2 Process of making CFTR modulators CFTR, SLC26A4, TMEM109 THRB 2612/4885MEN1 2440/4885KMT2A 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.